Canada markets close in 3 hours 37 minutes
  • S&P/TSX

    20,633.06
    +37.17 (+0.18%)
     
  • S&P 500

    4,365.01
    +15.08 (+0.35%)
     
  • DOW

    34,405.82
    +237.73 (+0.70%)
     
  • CAD/USD

    0.7860
    -0.0035 (-0.45%)
     
  • CRUDE OIL

    86.91
    -0.44 (-0.50%)
     
  • BTC-CAD

    46,209.27
    -2,747.33 (-5.61%)
     
  • CMC Crypto 200

    832.26
    +12.75 (+1.56%)
     
  • GOLD FUTURES

    1,794.10
    -35.60 (-1.95%)
     
  • RUSSELL 2000

    1,965.73
    -10.73 (-0.54%)
     
  • 10-Yr Bond

    1.8010
    -0.0470 (-2.54%)
     
  • NASDAQ

    13,509.68
    -32.44 (-0.24%)
     
  • VOLATILITY

    30.67
    -1.29 (-4.04%)
     
  • FTSE

    7,554.31
    +84.53 (+1.13%)
     
  • NIKKEI 225

    26,170.30
    -841.03 (-3.11%)
     
  • CAD/EUR

    0.7049
    +0.0029 (+0.41%)
     

BioSyent Releases Q3 and YTD 2021 Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
·6 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • BIOYF

MISSISSAUGA, Ontario, Nov. 18, 2021 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and nine months ended September 30, 2021. Key highlights include:

  • Third quarter (Q3) 2021 Net Revenues of $6,690,419 increased by 16% versus Q3 2020

  • Year-to-date (YTD) 2021 Net Revenues of $21,399,562 increased by 29% versus YTD 2020

  • Canadian Pharmaceutical Net Revenues in Q3 2021 of $6,409,809 increased by 17% versus Q3 2020

  • YTD 2021 Canadian Pharmaceutical Net Revenues of $19,313,894 increased by 22% versus YTD 2020

  • Q3 2021 International Pharmaceutical Net Revenues of $Nil as compared to $6,306 in Q3 2020

  • YTD 2021 International Pharmaceutical Net Revenues of $1,305,317 increased by 675% versus YTD 2020

  • Q3 2021 EBITDA1 of $2,293,713 increased by 64% versus Q3 2020

  • YTD 2021 EBITDA1 of $6,144,581 increased by 38% versus YTD 2020

  • Q3 2021 Net Income After Taxes (NIAT) of $1,721,320 increased by 80% versus Q3 2020

  • YTD 2021 NIAT of $4,403,762 increased by 41% versus YTD 2020

  • Q3 2021 NIAT percentage to Net Revenues of 26% compares to 17% in Q3 2020

  • YTD 2021 NIAT percentage to Net Revenues of 21% compares to 19% in YTD 2020

  • Q3 2021 Fully Diluted EPS of $0.13 was $0.06 higher than Q3 2020 Fully Diluted EPS of $0.07

  • YTD 2021 Fully Diluted EPS of $0.34 was $0.10 higher than YTD 2020 Fully Diluted EPS of $0.24

  • Fully Diluted EPS for the Trailing Twelve Months ended September 30, 2021 was $0.39 as compared to $0.32 for the Trailing Twelve Months ended September 30, 2020

  • As at September 30, 2021, the Company had cash, cash equivalents, and short-term investments totalling $27,101,933, a 6% increase as compared to $25,577,706 as at December 31, 2020

  • Total Shareholders’ Equity increased by 13% to $30,332,390 at September 30, 2021 from $26,795,956 at December 31, 2020

  • Return on Equity for the Trailing Twelve Months ended September 30, 2021 was 18% as compared to 17% for the Trailing Twelve Months ended September 30, 2020

  • During YTD 2021, repurchased and cancelled a total of 79,700 common shares under a Normal Course Issuer Bid (NCIB)

“Q3 2021 marked BioSyent’s 45th consecutive profitable quarter as well as its most profitable quarter to date with record NIAT of $1,721,320 increasing by 80% over Q3 2020. Our established Canadian pharmaceutical brands, led by FeraMAX® Pd, continued to drive topline growth and profitability while we continued to invest in launch brands, resulting in a healthy 26% net profit margin overall in the quarter. Together with growth contributed by launch brands, Tibella® and Combogesic®, Canadian pharmaceutical sales showed double-digit growth overall for the quarter as we navigated through the ongoing impacts of COVID-19 on the business and healthcare environments in Canada,” commented Mr. René Goehrum, President and CEO of BioSyent. “We generated $2.3 million of cash during Q3 2021 and have maintained our commitment to our NCIB, having bought back 142,650 shares to date during 2021. In October of this year, we launched FeraMAX® Pd Powder 15, the second product using the patented PDIC oral iron delivery system, following on the success of FeraMAX® Pd Therapeutic 150, launched in November 2020. We are planning for further innovative FeraMAX® Pd product extensions while we continue to invest in our launch brands and future additions to our product portfolio.”

The CEO’s presentation on the Q3 2021 Results is available at the following link: www.biosyent.com/q3-21/.

The Company’s Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three and nine months ended September 30, 2021 and 2020 will be posted on www.sedar.com on November 18, 2021.

Q3 2021 Interim Financial Statements PDF available at: http://ml.globenewswire.com/Resource/Download/222ed00f-b757-4727-becb-1538d0102244

Q3 2021 MD&A PDF available at: http://ml.globenewswire.com/Resource/Download/80248e90-986e-49e5-a05c-9503a469be08

For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol “RX”, BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the Company has 12,594,758 common shares outstanding.

BioSyent Inc.

Interim Unaudited Condensed Consolidated Statements of Net Income and Comprehensive Income

In Canadian Dollars

Q3 2021

Q3 2020

% Change

YTD 2021

YTD 2020

% Change

Net Revenues

6,690,419

5,771,739

16

%

21,399,562

16,605,840

29

%

Cost of Goods Sold

1,433,239

1,277,645

12

%

4,583,301

3,581,708

28

%

Gross Profit

5,257,180

4,494,094

17

%

16,816,261

13,024,132

29

%

Operating Expenses and Finance Income/Costs

3,057,582

3,191,544

-4

%

10,984,378

8,823,283

24

%

Net Income Before Taxes

2,199,598

1,302,550

69

%

5,831,883

4,200,849

39

%

Tax (including Deferred Tax)

478,278

346,641

38

%

1,428,121

1,071,216

33

%

Net Income After Taxes

1,721,320

955,909

80

%

4,403,762

3,129,633

41

%

Net Income After Taxes % to Net Revenues

26

%

17

%

21

%

19

%

EBITDA

2,293,173

1,399,781

64

%

6,144,581

4,460,350

38

%

EBITDA % to Net Revenues

34

%

24

%

29

%

27

%

  1. EBITDA – is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.

BioSyent Inc.

Interim Unaudited Condensed Consolidated Statements of Financial Position

AS AT

September 30, 2021

December 31, 2020

% Change

ASSETS

Cash, cash equivalents and short term investments

$

27,101,933

$

25,577,706

6

%

Trade and other receivables

3,742,588

1,815,015

106

%

Inventory

2,469,958

2,073,561

19

%

Prepaid expenses and deposits

479,810

307,599

56

%

Loans receivable

419,056

-

100

%

CURRENT ASSETS

34,213,345

29,773,881

15

%

Property and equipment

1,967,747

2,161,698

-9

%

Intangible assets

895,437

1,007,822

-11

%

Loans receivable

182,744

597,332

-69

%

Deferred tax asset

66,058

30,481

117

%

TOTAL NON CURRENT ASSETS

3,111,986

3,797,333

-18

%

TOTAL ASSETS

$

37,325,331

$

33,571,214

11

%

LIABILITIES AND SHAREHOLDERS' EQUITY

CURRENT LIABILITIES

$

5,430,810

$

5,138,674

6

%

NON CURRENT LIABILITIES

1,562,131

1,636,584

-5

%

Long term debt

-

-

Total Equity

30,332,390

$

26,795,956

13

%

TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY

$

37,325,331

$

33,571,214

11

%

For further information please contact:

Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.



Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting